Navigation Links
Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
Date:9/19/2007

Prodrugs Generated from Targanta's Novel Drug Discovery Platform

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released detailed data from two studies highlighting the in vitro activity and in vivo efficacy of its proprietary prodrugs in osteomyelitis models. Results are being presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL and represent the first data sets from this proprietary platform.

Osteomyelitis is an acute or chronic bone infection predominantly caused by staphylococci, requiring treatment through prolonged parenteral antibiotic administration and, often, surgical intervention. There are currently no antibiotics approved to treat osteomyelitis, which has been designated by the U.S. Food and Drug Administration (FDA) as a significant unmet medical need. Targanta has developed a novel drug discovery platform through which it tethers bone-targeting bisphosphonates to approved antibiotics to generate molecules that deliver the antibiotics directly to the bone, targeting the site of infection.

In the first study, entitled, "Preparation and In Vitro Evaluation of Fluoroquinolone Prodrugs for the Prevention and Treatment of Osteomyelitis," researchers synthesized a total of 45 bisphosphonated fluoroquinolone prodrugs by tethering ciprofloxacin, gatifloxacin or moxifloxacin to a bisphosphonate via cleavable linkers. The affinity of the prodrugs for bone was determined by exposing individual compounds to a suspension of bovine bone powder. Most were found to bind near quantitatively to bone powder and released the parent fluoroquinolone at various rates. In this in vitro study, the high affinity displayed by the compounds for bone powder and their ability to regenerate active parent compound over time suggests they could be used to concentrate antibacterial fluoroquinolones into the bone via systemic administration.

In
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
(Date:7/10/2014)... JORDAN, Utah , July 10, 2014  BC ... solutions, and MiE America , Inc., a leading ... have entered into a long-term agreement naming BC Technical ... the US. MiE and BC Technical ... strategic agreement to establish BC Technical as the service ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ST. LOUIS , Feb. 1 Stereotaxis (Nasdaq: ... featured Dr. Mauricio Arruda , a leading electro-physiologist ... in Cleveland, Ohio , performing a live cardiac ablation ... The patient was a 69 year old woman who suffered ...
... BRISBANE, Calif. , Feb. 1 InterMune, ... Food and Drug Administration,s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) ... for pirfenidone on March 9, 2010 .  Pirfenidone is ... idiopathic pulmonary fibrosis (IPF).   , "There is an urgent ...
Cached Medicine Technology:Stereotaxis System Procedure Featured on NBC's The TODAY Show 2InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 2InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 3InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 4InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010 5
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Nature, not ... intelligence of individual chimpanzees, a new study finds. ... it comes to cognitive [thinking] abilities in chimpanzees," William ... Atlanta, said in a news release from the journal ... give insight into the evolution of intelligence in humans, ...
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Men who ... aggressive prostate cancer, a new study suggests. But ... several urologists not involved with the study said more ... are truly accurate. For the study, Harvard researchers ... were followed for 24 years, starting in 1986. During ...
(Date:7/10/2014)... More than 200 experts on aggression, who research issues ... attend the 21st World Meeting of the International Society ... Hotel, July 15-19. , Georgia State University is hosting ... year on alternating continents. , "We are excited to ... different countries, which will help produce fresh ideas about ...
(Date:7/10/2014)... of Health and Human Services (HHS) has announced a ... Seidman Cancer Center totaling $4.7 million to support a ... with complex cancer. , Titled "Evidence-Conformant Oncology Care," ... UH to enhance care for adult cancer patients with ... health care utilization. , "We believe that ...
(Date:7/10/2014)... shown that more severe illness and even death are ... infection after developing influenza. Now, however, a team of ... if you reverse the order of infection, the bacteria ... protect against a bad case of the flu. ... which is described as a bacterial virulence factor, might ...
Breaking Medicine News(10 mins):Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2
... ,Hidden Health Tax, is the Undisclosed Premium Surcharge that Pays ... People Join the Ranks of the Uninsured, the ,Hidden Health ... Higher in 2009WASHINGTON, May 28 The so-called ... $1,017 in 2008 according to a report released today by ...
... Elsevier, would like to announce the publication of ... Treatment by Peter Miller, PhD. , The ... the field of addictions treatment is leading to ... based solely on clinical intuition rather than hard ...
... 2009) Kevin Bruhn, PhD, is the winner of the ... at nurturing excellence and providing support for a young scientist ... to LA BioMed in 2005 after receiving his PhD in ... Los Angeles in 2004 and completing a postdoctoral fellowship in ...
... BIRMNGHAM, Ala. An experimental drug derived from cottonseed ... widely considered the most lethal brain cancer, said researchers ... The new results are from a Phase II clinical ... compound in cottonseed that overcomes the abnormal growth patterns ...
... fractional laser was featured today on NBC,s Today ... for scars. During the broadcast, triplets who were severely ... story and discussed recent treatments with the Lumenis UltraPulse ... and DeepFX technologies, the triplets Jordan, Trae and Chandra ...
... Deliciously Cool, Smooth Drink While It,s HotBATTLE CREEK, Mich., May 28 ... season doesn,t feature the bells and whistles of most sought-after new ... to get their hands on it just the same. ... (R) brand is introducing the brand,s first ...
Cached Medicine News:Health News:'Hidden Health Tax' for Family Health Care Coverage Climbed to $1,017 in 2008 2Health News:'Hidden Health Tax' for Family Health Care Coverage Climbed to $1,017 in 2008 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 2Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 4Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 2Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 3Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 4
...
... Miditron Junior II ... urinalysis analyser for standardised ... hardware and software features ... high performance and convenience ...
... The Assistant Free ... retractors utilizing Velcro® straps. ... of the surgeon's operative ... personnel. Three retractor styles ...
... for four corner fusion of the capitate, ... hand. The plate is intended for use ... of function due to SLAC and SNAC ... rheumatoid arthritis. When combined with the specially ...
Medicine Products: